SCHEMBL4858097

SCHEMBL4858097

COc1cc(Cl)ccc1C(O)c1cncs1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
CYP3A4 P08684 2/20 0.35
PDE10A Q9Y233 1/20 0.35
ALPL P05186 2/20 0.35
MAPK1 P28482 1/20 0.35
CYP19A1 P11511 1/20 0.35
S1PR3 Q99500 1/20 0.35
IRAK4 Q9NWZ3 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
CYP17A1 P05093 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2C19 P33261 1/20 0.34
HPGD P15428 1/20 0.34
HTT P42858 1/20 0.34
HSD17B10 Q99714 1/20 0.34
RXFP1 Q9HBX9 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4856771 0.73 GAA (0.50) MEN1KMT2ACYP3A4ALPLMAPK1
SCHEMBL4849513 0.73 CTSA (0.48) CNR2KCNMA1
SCHEMBL14033955 0.71 SLC6A3 (0.45) KMT2ACYP19A1HPGDSLC6A2SLC6A3
SCHEMBL2616495 0.71 TSHR (0.42) KMT2AMAPK1ALDH1A1
SCHEMBL6239164 0.71 LPAR1 (0.44) MEN1KMT2AS1PR3ALDH1A1KDM4E
SCHEMBL4849102 0.70 ALDH1A1 (0.38) CNR2MEN1KMT2AS1PR3IRAK4
SCHEMBL23931527 0.70 IDO1 (0.43) MEN1KMT2AHTTSLC6A2SLC6A3
SCHEMBL23931525 0.70 IDO1 (0.43) MEN1KMT2AHTTSLC6A2SLC6A3
SCHEMBL30011604 0.70 IDO1 (0.43) MEN1KMT2AHTTSLC6A2SLC6A3
SCHEMBL1911429 0.67 LPAR1 (0.50) MEN1KMT2AS1PR3ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456169-B2 Heterocyclic kinase inhibitors ABBOTT LABORATORIES INC. (US) 2008-11-25 US disclosed
US-20070254867-A1 Heterocyclic Kinase Inhibitors ABBVIE INC. 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254867-A1 Heterocyclic Kinase Inhibitors MAP3K20, MAP3K19, MAP4K2 CNR2 3224/4885MEN1 2238/4885KMT2A 1376/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.